Cargando…

Identification of therapeutic targets applicable to clinical strategies in ovarian cancer

BACKGROUND: shRNA-mediated lethality screening is a useful tool to identify essential targets in cancer biology. Ovarian cancer (OC) is extremely heterogeneous and most cases are advanced stages at diagnosis. OC has a high response rate initially, but becomes resistant to standard chemotherapy. We p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Marianne K., Caplen, Natasha, Chakka, Sirisha, Hernandez, Lidia, House, Carrie, Pongas, Georgios, Jordan, Elizabeth, Annunziata, Christina M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4997769/ https://www.ncbi.nlm.nih.gov/pubmed/27558154 http://dx.doi.org/10.1186/s12885-016-2675-5

Ejemplares similares

BRD4 facilitates DNA damage response and represses CBX5/Heterochromatin protein 1 (HP1)
por: Pongas, Georgios, et al.
Publicado: (2017)

In vitro Enrichment of Ovarian Cancer Tumor-initiating Cells
por: House, Carrie D., et al.
Publicado: (2015)

Recent Technological Advances in Using Mouse Models to Study Ovarian Cancer
por: House, Carrie Danielle, et al.
Publicado: (2014)

Identification of novel molecular regulators of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in breast cancer cells by RNAi screening
por: Garimella, Sireesha V, et al.
Publicado: (2014)

PI3Kδ inhibition causes feedback activation of PI3Kα in the ABC subtype of diffuse large B-cell lymphoma
por: Pongas, Georgios N., et al.
Publicado: (2017)

Drugs Targeting Tumor-Initiating Cells Prolong Survival in a Post-Surgery, Post-Chemotherapy Ovarian Cancer Relapse Model
por: Harrington, Brittney S., et al.
Publicado: (2020)

BEZ235: When Promising Science Meets Clinical Reality
por: Pongas, Georgios, et al.
Publicado: (2016)

Recent Advances in the Management of Patients with Relapsed/Refractory Follicular Lymphoma
por: Pongas, Georgios, et al.
Publicado: (2021)

IΚΚε cooperates with either MEK or non-canonical NF-kB driving growth of triple-negative breast cancer cells in different contexts
por: House, Carrie D., et al.
Publicado: (2018)

HIV-Associated Lymphomas: Progress and New Challenges
por: Pongas, Georgios N., et al.
Publicado: (2022)

Smac-mimetic enhances antitumor effect of standard chemotherapy in ovarian cancer models via Caspase 8-independent mechanism
por: Hernandez, Lidia F., et al.
Publicado: (2021)

Topotecan synergizes with CHEK1 (CHK1) inhibitor to induce apoptosis in ovarian cancer cells
por: Kim, Marianne K, et al.
Publicado: (2015)

NF-κB Signaling Modulates miR-452-5p and miR-335-5p Expression to Functionally Decrease Epithelial Ovarian Cancer Progression in Tumor-Initiating Cells
por: Kamdar, Rahul D., et al.
Publicado: (2023)

Therapeutic strategies in epithelial ovarian cancer
por: Kim, Ayako, et al.
Publicado: (2012)

UGDH promotes tumor-initiating cells and a fibroinflammatory tumor microenvironment in ovarian cancer
por: Harrington, Brittney S., et al.
Publicado: (2023)

NF-κB Signaling in Ovarian Cancer
por: Harrington, Brittney S., et al.
Publicado: (2019)

Mantle cell lymphoma involving the thyroid gland
por: Pongas, Georgios N, et al.
Publicado: (2021)

Fusion transcripts: Unexploited vulnerabilities in cancer?
por: Neckles, Carla, et al.
Publicado: (2019)

The small molecule NSC676914A is cytotoxic and differentially affects NFκB signaling in ovarian cancer cells and HEK293 cells
por: Sagher, Ethan, et al.
Publicado: (2014)

Tumor Microenvironment in Ovarian Cancer: Function and Therapeutic Strategy
por: Yang, Yanfei, et al.
Publicado: (2020)

Novel Therapeutic Strategies for Ovarian Cancer Stem Cells
por: Terraneo, Nastassja, et al.
Publicado: (2020)

Ferroptosis in Ovarian Cancer: A Novel Therapeutic Strategy
por: Li, Lanyu, et al.
Publicado: (2021)

Therapeutic Strategies for Targeting Ovarian Cancer Stem Cells
por: Yang, Wookyeom, et al.
Publicado: (2021)

Driving Immune Responses in the Ovarian Tumor Microenvironment
por: Ning, Franklin, et al.
Publicado: (2021)

Targeting the PI3K/AKT/mTOR pathway in epithelial ovarian cancer, therapeutic treatment options for platinum-resistant ovarian cancer
por: Rinne, Natasha, et al.
Publicado: (2021)

Targeting Mitochondria as Therapeutic Strategy for Metabolic Disorders
por: Sorriento, Daniela, et al.
Publicado: (2014)

Ovarian cancer: Current status and strategies for improving therapeutic outcomes
por: Chandra, Ashwin, et al.
Publicado: (2019)

Revisiting therapeutic strategies for ovarian cancer by focusing on redox homeostasis
por: Kobayashi, Hiroshi, et al.
Publicado: (2022)

Therapeutic strategies targeting folate receptor α for ovarian cancer
por: Mai, Jia, et al.
Publicado: (2023)

Loss of compensatory pro-survival and anti-apoptotic modulator, IKKε, sensitizes ovarian cancer cells to CHEK1 loss through an increased level of p21
por: Kim, Marianne K., et al.
Publicado: (2014)

The 8q24 Gene Desert: An Oasis of Non-Coding Transcriptional Activity
por: Huppi, Konrad, et al.
Publicado: (2012)

Caspase 8 expression may determine the survival of women with ovarian cancer
por: Kim, M, et al.
Publicado: (2016)

PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer
por: Annunziata, Christina M, et al.
Publicado: (2010)

Matrix Drug Screen Identifies Synergistic Drug Combinations to Augment SMAC Mimetic Activity in Ovarian Cancer
por: Noonan, Anne M., et al.
Publicado: (2020)

SLFN11 promotes CDT1 degradation by CUL4 in response to replicative DNA damage, while its absence leads to synthetic lethality with ATR/CHK1 inhibitors
por: Jo, Ukhyun, et al.
Publicado: (2021)

SpliceCenter: A suite of web-based bioinformatic applications for evaluating the impact of alternative splicing on RT-PCR, RNAi, microarray, and peptide-based studies
por: Ryan, Michael C, et al.
Publicado: (2008)

Therapeutic Strategies for Ovarian Cancer in Point of HGF/c-MET Targeting
por: Kim, Hyun Jung
Publicado: (2022)

Premature Ovarian Insufficiency: Procreative Management and Preventive Strategies
por: Chae-Kim, Jennifer J., et al.
Publicado: (2018)

Identification of Novel Therapeutic Targets in Microdissected Clear Cell Ovarian Cancers
por: Stany, Michael P., et al.
Publicado: (2011)

Aberrant Cholesterol Metabolism in Ovarian Cancer: Identification of Novel Therapeutic Targets
por: He, Jiangnan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ank9meqrnqq9kae0esq2im87n3